Investing.comCodex · 实盘不做把握 2/10
北京时间·🕒 发布 20:36:39时区推断·⟳ 抓取 20:38:56·⚡ 决策 07-28 20:39:34 +38s·91.0 天前
Bicara Therapeutics 任命两名新董事
本次事件只是临床阶段生物科技公司董事会人事调整，没有披露临床数据、监管进展、融资、并购或商业化增量。
📄 原文Investing.com↗ 原文
Bicara Therapeutics adds two directors to board
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCA…
不做 Bicara Therapeutics（BCAX.US）
普通董事会人事调整，无明确收入、利润、临床、监管或并购催化，无法形成正期望同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次事件只是临床阶段生物科技公司董事会人事调整，没有披露临床数据、监管进展、融资、并购或商业化增量。
主要风险
- 标题与正文不一致，正文实际为 Bicara Therapeutics 董事任命，信号质量偏低。
原文全文
展开原文 · 2,030 字
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX) announced today the appointment of Jeremy Bender and Christy Oliger to its board of directors, according to a press release statement.
Bender most recently served as chief executive officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026. He led the company through the approval and launch of OJEMDA for pediatric low-grade glioma and the company’s approximately $2.5 billion acquisition. Bender holds more than 20 years of experience in biotechnology corporate strategy and operations. He previously held positions at Gilead Sciences as vice president of corporate development from March 2018 to September 2020, and served in leadership roles at Tizona Therapeutics and Sutro Biopharma. He currently sits on the boards of Mereo BioPharma Group and Aura Biosciences.
Oliger brings more than 30 years of commercial and operating experience in biopharmaceutical organizations. She served as senior vice president of the Oncology Business Unit at Genentech from 2017 to 2020, managing a portfolio of 15 products contributing U.S. revenue exceeding $13 billion. She previously held roles as senior vice president and business unit head for Neurology, Rare Disease, and Infectious Disease at Genentech. Oliger currently serves on the boards of Vera Therapeutics, Karyopharm Therapeutics, and Replimune Inc.
The company also announced that Kiran Mazumdar-Shaw has retired from the board. Mazumdar-Shaw was a founding board member who provided initial seed capital and strategic guidance to the company.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. The company’s lead program is ficerafusp alfa, a bifunctional antibody being developed for head and neck squamous cell carcinoma and other solid tumor types.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BOSTON - Bicara Therapeutics Inc. (NASDAQ:BCAX) announced today the appointment of Jeremy Bender and Christy Oliger to its board of directors, according to a press release statement.
Bender most recently served as chief executive officer at Day One Biopharmaceuticals through its acquisition by Servier in 2026. He led the company through the approval and launch of OJEMDA for pediatric low-grade glioma and the company’s approximately $2.5 billion acquisition. Bender holds more than 20 years of experience in biotechnology corporate strategy and operations. He previously held positions at Gilead Sciences as vice president of corporate development from March 2018 to September 2020, and served in leadership roles at Tizona Therapeutics and Sutro Biopharma. He currently sits on the boards of Mereo BioPharma Group and Aura Biosciences.
Oliger brings more than 30 years of commercial and operating experience in biopharmaceutical organizations. She served as senior vice president of the Oncology Business Unit at Genentech from 2017 to 2020, managing a portfolio of 15 products contributing U.S. revenue exceeding $13 billion. She previously held roles as senior vice president and business unit head for Neurology, Rare Disease, and Infectious Disease at Genentech. Oliger currently serves on the boards of Vera Therapeutics, Karyopharm Therapeutics, and Replimune Inc.
The company also announced that Kiran Mazumdar-Shaw has retired from the board. Mazumdar-Shaw was a founding board member who provided initial seed capital and strategic guidance to the company.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. The company’s lead program is ficerafusp alfa, a bifunctional antibody being developed for head and neck squamous cell carcinoma and other solid tumor types.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。